Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of rosiglitazone versus placebo on cardiovascular performance and myocardial triglyceride.

Trial Profile

Effect of rosiglitazone versus placebo on cardiovascular performance and myocardial triglyceride.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Apr 2012

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 03 Apr 2012 Actual patient number changed from 111 to 150 as eported by ClinicalTrials.gov.
    • 03 Apr 2012 Company added in association field as reported by ClinicalTrials.gov.
    • 03 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top